Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

This is an open-label Phase 1 dose-escalation study in patients with solid tumors treated
with STA-9090 (ganetespib) to evaluate for safety, tolerance and efficacy.

Inclusion Criteria:

- Patients must be documented to be refractory or not candidates for current approved
therapies. - Must have anECOG status 0-2. - Peripheral neuropathy ?2.

- Must have acceptable organ and marrow function per protocol parameters.

- No clinically significant ventricular arrythmias or ischemia.

Exclusion Criteria:

- Must not be pregnant or breastfeeding. -No chemotherapy or radiation within 3 weeks..

- No previous radiation to >25% of total bone marrow.

- No previous high dose chemotherapy with autologous or allogeniec hematopoietic stem
cell transplantation.

- No primary brain tumors or active brain metastases.

- No use of any investigational agents within 4 weeks.

- No treatment with chronic immunosuppressants.

- No uncontrolled, intercurrent illness.